Highest-materiality recent filing
Myriad Genetics to sell prenatal health testing business to Labcorp for $210 million cash
Myriad Genetics agreed to sell its Prenatal Health testing business, including Prequel, Foresight, SneakPeek and FirstGene, to Labcorp for $210 million cash plus closing inventory value.
Q2 revenue $190.7M (-11% YoY); test volumes 379K flat; avg revenue per test down 9% including $11M prior-period estimate adjustment.
Myriad Genetics Q1 revenue $200.4M, GAAP net loss $34.1M; reiterates FY guidance
GAAP net loss $34.1M ($0.36/sh); adjusted loss $0.09/sh; adjusted EBITDA negative $4.5M.
Myriad Genetics Q4 2025 revenue $209.8M, net loss $7.9M; reiterates 2026 guidance
GAAP net loss $7.9M ($0.08 loss per share); adjusted EPS $0.04.
Myriad Genetics prelim Q4 revenue $207-209M, FY25 $822-824M; FY26 guidance $860-880M
Preliminary Q4 2025 total revenue $207-209M; full year 2025 revenue $822-824M.
Myriad Genetics Q3 revenue $205.7M (-4% YoY); adjusted EPS $0.00; reaffirms FY2025 guidance
Q3 revenue $205.7M, down 4% YoY; flat excluding $8.1M headwinds (UNH GeneSight loss, EndoPredict divestiture).
Q3 revenue $205.7M, down 4% YoY; flat excluding $8.1M in headwinds from UNH GeneSight coverage loss and EndoPredict divestiture.
Myriad Genetics appoints Ben Wheeler as CFO; reaffirms FY2025 guidance
Scott Leffler stepped down as CFO effective Aug 15, 2025; will consult through Sept 2, 2025.
Myriad Genetics Q2 revenue $213.1M (+1% YoY); raises FY2025 revenue guidance
GAAP net loss $330.5M ($3.57/share) includes $316.7M impairment; adjusted EPS $0.05.
Myriad Genetics closes $200M credit facility with OrbiMed; $125M funded
Five-year senior secured term loan; $125M funded at closing, $75M delayed draw available through June 2027.
Myriad Genetics Q1 revenue down 3% to $196M; net loss of $0.1M; lowers FY2025 guidance
GAAP net loss $0.1M ($0.00 EPS); adjusted EPS $(0.03). Revenue of $196M declined 3% YoY.
Myriad Genetics: CEO succession plan; Q4 revenue $211M (+7%), FY 2024 revenue $838M (+11%)
CEO Paul J. Diaz resigns effective April 30, 2025; COO Samraat S. Raha appointed President, CEO, and Board member.
Myriad Genetics reports preliminary Q4 rev $209-211M, FY2025 adj EPS guidance $0.07-0.11
Q4 2024 preliminary revenue $209-211M (+6-7% YoY); GAAP diluted loss $(0.72)-(0.62)/share; adj EPS $0.03-$0.04.
Myriad Genetics Q3 revenue +11% to $213M, adj EPS $0.06; UNH to drop GeneSight coverage Jan 2025
Q3 revenue $213M (+11% YoY); GAAP net loss $22.1M improved from $61.3M loss; adj EBITDA $14.1M vs $1.4M.
Myriad Genetics discontinues part two of GeneSight study; control group deemed unreliable
Part one (April 2024) showed 29% drop in all-cause hospitalizations and 39% drop in psychiatric-related hospitalizations 180 days post-GeneSight.
Myriad Genetics Q2 revenue $212M (+15% YoY); raises FY2024 guidance, adjusted EPS $0.05
Revenue $212M (+15% YoY); GAAP EPS $(0.41) vs $(1.42) YoY; adjusted EPS $0.05 vs $(0.08).
Myriad Genetics Q1 revenue $202M (+12% YoY), positive adjusted EBITDA $4M, reiterates FY guidance
Q1 revenue $202.2M (+12% YoY); GAAP net loss narrowed to $26M from $55M.
Myriad Genetics Q4 2023 revenue $197M (+11% YoY); adjusted EPS $0.04; raises FY2024 revenue guidance
Q4 revenue $196.6M (+11% YoY); full-year 2023 revenue $753.2M (+11% YoY).
Myriad Genetics prelim Q4 revenue $196-197M; GAAP EPS loss ($0.35)-($0.36); adjusted EPS $0.02-0.03
Preliminary Q4 2023 revenue $196-197M; GAAP diluted EPS loss ($0.35)-($0.36); adjusted EPS $0.02-$0.03.
Myriad Genetics CFO Bryan Riggsbee retires; Scott Leffler named successor effective Jan 29, 2024
Riggsbee steps down as CFO by Jan 31, 2024; will serve as strategic advisor through March 31, 2024.
Myriad Genetics raises ~$110M via public offering of 6.47M shares at $17/sh
Entered underwriting agreement with Goldman Sachs, Morgan Stanley, and Wells Fargo to sell 6,470,588 shares at $17.00/share.
Myriad Genetics prices upsized 6.47M-share offering at $17.00 for ~$110M gross
Offering of 6,470,588 shares upsized; priced at $17.00/share; expected gross proceeds ~$110M.
Myriad Genetics Q3 revenue $191.9M, up 23% YoY; raises FY2023 guidance, introduces FY2024 guidance
Q3 revenue $191.9M (+23% YoY); GAAP EPS -$0.75, adjusted EPS -$0.03.
Myriad Genetics secures multi-year UnitedHealthcare contract renewal through 2027
New agreement covers tests: MyRisk, MyChoice CDx, BRACAnalysis CDx, Foresight, Prequel, GeneSight, Prolaris.
Myriad Genetics COO Nicole Lambert to step down Oct 31; remains consultant through Mar 2024
COO Nicole Lambert will depart as of Oct 31, 2023; will provide consulting services through Mar 31, 2024.
Myriad Genetics Q2 revenue $183.5M, settles securities class action for $77.5M
Q2 revenue $183.5M, up 2% YoY; diluted GAAP EPS $(1.42), adjusted EPS $(0.08).
Myriad Genetics Q1 revenue $181.2M (+10% YoY); raises FY23 revenue guidance midpoint
Q1 GAAP EPS $(0.67); adjusted EPS $(0.21); revenue $181.2M (+10% YoY).
Myriad Genetics Q4 revenue $177.8M (+11% YoY); GAAP EPS $(0.52), adjusted EPS $(0.12)
Q4 testing volumes up 26% YoY; hereditary cancer +16%, GeneSight +23%.
Revenue $156.4M (-2% YoY); GAAP EPS $(0.43), adjusted EPS $(0.19).
Myriad Genetics Q2 revenue $179.3M (+7% ex-divestitures); GAAP EPS -$0.18; cuts FY EPS guidance
GAAP diluted EPS of $(0.18); adjusted EPS $0.04, down from $0.12 YoY.
Myriad Genetics amends credit agreement: revolver cut to $200M, covenants waived through July 2023
Revolving commitments reduced from $300M to $200M, further to $150M by Dec 31, 2022; potential additional $50M cut from asset sales.
Revenue $164.9M (+11% YoY ex-divested); GAAP EPS $(0.26) improved from $(0.52); adjusted EPS $(0.03) from $(0.06).
On October 6, 2026, Myriad Genetics, Inc. (the “Company”) entered into a Separation Agreement and Release of Claims (the “Separation Agreement”) with Brian Donnelly, the Company’s former Chief Commercial Officer. As previously disclosed, Mr. Donnelly departed from his position as Chief Commercial Officer of the Company, effective September 16, 2026.
the Board appointed Samraat S. Raha, the Company's Chief Operating Officer, to succeed Mr. Diaz as its President and Chief Executive Officer on the Effective Date.
the Board also appointed Mr. Raha to the Board to serve as a Class II director with a term expiring at the Company’s 2025 Annual Meeting of Stockholders as of the Effective Date to fill the vacancy on the Board that will be created by Mr. Diaz’ resignation.
Paul J. Diaz, the Company’s President and Chief Executive Officer, announced on February 24, 2025 that he will step down from those positions, and resign from the Company’s Board of Directors (the “Board”), on April 30, 2025
On December 15, 2023, R. Bryan Riggsbee, Chief Financial Officer and principal financial officer of Myriad Genetics, Inc. (the “Company”) and the Company mutually reached an agreement that Mr. Riggsbee would step down from such position, effective upon the earlier of (1) the date that a new Chief Financial Officer and principal financial officer commences his or her employment at the Company and (2) January 31, 2024.
On December 15, 2023, the Board appointed Scott J. Leffler (“Mr. Leffler”) as the Company's Chief Financial Officer and principal financial officer, effective as of his first date of employment, January 29, 2024.
On October 16, 2023, the Board of Directors (the "Board") of Myriad Genetics, Inc. (the "Company" or "Myriad") appointed Samraat S. Raha ("Mr. Raha") as the Company's Chief Operating Officer, effective as of December 11, 2023.
On October 4, 2023, Nicole Lambert, Chief Operating Officer of Myriad Genetics, Inc. (the “Company”) and the Company mutually reached an agreement that Ms. Lambert would step down from such position, effective October 31, 2023
On June 28, 2022, Dennis Langer, a member of the Board of Directors of Myriad Genetics, Inc. (the “Company”), notified the Company that he is resigning as a director, effective June 30, 2022.
On June 2, 2022, the Board of Directors of Myriad Genetics, Inc. (the "Company") designated Natalie Munk, the Company's Chief Accounting Officer, to serve as the Company's principal accounting officer.
As previously disclosed, Dr. Lanchbury announced his retirement as Chief Scientific Officer of the Company, effective January 14, 2022.
On January 3, 2022, Jerry Lanchbury, Ph.D., notified Myriad Genetics, Inc. (the "Company") of his retirement as Chief Scientific Officer of the Company, effective January 14, 2022.
Max materiality 0.90 · Median 0.65 · Most common event earnings